Home/Filings/4/0001127602-24-005449
4//SEC Filing

Shah Prem S 4

Accession 0001127602-24-005449

CIK 0000064803other

Filed

Feb 15, 7:00 PM ET

Accepted

Feb 16, 6:46 PM ET

Size

18.1 KB

Accession

0001127602-24-005449

Insider Transaction Report

Form 4
Period: 2024-02-16
Shah Prem S
EVP and Group President
Transactions
  • Sale

    Common Stock

    2024-02-16$76.95/sh29,473$2,267,94739,764.762 total
Holdings
  • Phantom Stock Credits

    Exercise: $1.00Common Stock (33,754.62 underlying)
    33,754.62
  • Stock Option

    Exercise: $75.24From: 2021-08-31Exp: 2028-08-31Common Stock (26,580 underlying)
    26,580
  • Stock Option

    Exercise: $74.31From: 2024-04-01Exp: 2033-04-01Common Stock (89,073 underlying)
    89,073
  • Stock Option

    Exercise: $62.21From: 2019-04-01Exp: 2025-04-01Common Stock (846 underlying)
    846
  • Stock Option

    Exercise: $101.09From: 2023-04-01Exp: 2032-04-01Common Stock (41,580 underlying)
    41,580
  • Common Stock (Restricted)

    29,649
  • Stock Option

    Exercise: $58.34From: 2021-04-01Exp: 2030-04-01Common Stock (28,596 underlying)
    28,596
  • Stock Option

    Exercise: $74.30From: 2022-04-01Exp: 2031-04-01Common Stock (28,723 underlying)
    28,723
  • ESOP Common Stock

    4,788.942
  • Stock Unit (deferred)

    3,350.356
  • Stock Option

    Exercise: $54.19From: 2020-04-01Exp: 2029-04-01Common Stock (9,469 underlying)
    9,469
Footnotes (11)
  • [F1]Represents weighted average sale price for this group of sales, which occurred on the same trading day. Multiple sales were executed, with sales prices ranging between 76.93 to 76.99 per share.
  • [F10]Option became exercisable in four equal installments, commencing 4/1/2023.
  • [F11]Option becomes exercisable in four equal annual installments, commencing 4/1/2024.
  • [F2]Consists of Stock Units awarded pursuant to Issuer's 2010 & 2017 Incentive Compensation Plans, the receipt of which the reporting person has elected to defer.
  • [F3]Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
  • [F4]Reflects year-end company-match share credits under a non-qualified deferred compensation plan; share credits are payable in cash only, at such time as has been elected by the reporting person.
  • [F5]Option became exercisable in four equal installments commencing 04/01/2019. Additional options from this award have been exercised.
  • [F6]Option became exercisable in four equal installments commencing 04/01/2020. Additional options from this award have been exercised
  • [F7]Option became exercisable in four equal installments commencing 04/01/2021. Additional options from this award have been exercised.
  • [F8]Option became exercisable in three equal installments, commencing on 8/31/2021.
  • [F9]Option became exercisable in three equal installments commencing 04/01/2022.

Issuer

CVS HEALTH Corp

CIK 0000064803

Entity typeother

Related Parties

1
  • filerCIK 0001900910

Filing Metadata

Form type
4
Filed
Feb 15, 7:00 PM ET
Accepted
Feb 16, 6:46 PM ET
Size
18.1 KB